ライフサイエンスコーパス: selective drug

1 oxygenase inhibitor as compared with a COX-2 selective drug.

2 and a determination to develop targeted and selective drugs.

3 an facilitate development of more potent and selective drugs.

4 ecause this will ultimately aid in designing selective drugs.

5 ersity set, and the selective drugs from non-selective drugs.

6 n into consideration when developing subunit-selective drugs.

7 er-soluble, highly potent, and GluA2 subunit-selective drugs.

8 an ideal target for the discovery of subtype-selective drugs.

9 oncoproteins and enable the creation of more selective drugs.

10 te would allow for a broader range of tissue selective drugs.

11 urons and will facilitate the development of selective drugs.

12 l facilitate the development of CRF receptor selective drugs.

13 decrease in the affinity of the highly D(4)-selective drug 3-([4-(4-iodophenyl) piperazin-1-yl]methy

14 received microinfusions of the 5-HT receptor-selective drugs 8-OH-DPAT (0.025 or 0.1mug), WAY 100635

15 e of understanding the mechanisms underlying selective drug action and resistance for the development

16 is article provide a guide for the design of selective drugs against many prokaryotic and eukaryotic

17 ase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras c

18 Competition between PDE5/6-selective drugs and the inhibitory gamma-subunit for the

19 njected dopamine D1- and D2-receptor subtype selective drugs, and then evaluated behavioral responses

20 More selective drugs are available today, but this therapeuti

21 GABAA receptor subtype-selective drugs are therefore expected to provide novel

22 Highly selective drugs are urgently needed.

23 oinflammatory pathways and suggest PPARdelta-selective drugs as candidate therapeutics for atheroscle

24 Gene deletion or selective drug blockade of TRPC6 or cGMP/PKG activation

25 er of studies have shown that delta receptor-selective drugs can enhance their potency.

26 O-Me-cAMP to proximal tubules using a kidney-selective drug carrier approach resulted in prolonged ac

27 ntial for DEAdcCE-caged peptide sequences as selective drug carriers in the context of photocontrolle

28 This is the first study of selective drug delivery in humans using a novel PSA-acti

29 t levels of mobile ferrous iron (Fe(II)) for selective drug delivery in vivo.

30 eutically relevant target, as it can provide selective drug delivery to cancer cells.

31 provide an exciting alternative approach for selective drug delivery to tumor cells that may improve

32 This selective drug delivery translates into improved efficac

33 astly, bioimprints also have applications as selective drug delivery vehicles to tumours with the pot

34 or is a potential molecular target for tumor-selective drug delivery, including radiolabeled folate-c

35 ctivator, to obtain sustained, enhanced, and selective drug delivery, including various sized molecul

36 technology was demonstrated by an example of selective drug delivery.

37 terial infections and provide new routes for selective drug delivery.

38 type, this makes it an attractive target for selective drug delivery.

39 or is a potential molecular target for tumor-selective drug delivery.

40 orters, which hold great potential for tumor-selective drug delivery.

41 g electrodes, transducers for biosensors, or selective drug-delivery.

42 versity could have important implications in selective drug design against a wide range of ERalpha-re

43 t responses will enable novel routes for PTP-selective drug design, important for managing diseases s

44 n-competitive inhibitors and is a target for selective drug design.

45 ant differences which could be exploited for selective drug design.

46 cations for agonist-directed trafficking and selective drug design.

47 guanines is not sufficient to explain the GC-selective drug-DNA association, and the implications of

48 ely useful in the prediction of functionally selective drug effects.

49 be a target for developing subtype or state-selective drugs for nAChRs.

50 icate functional assays intended to identify selective drugs for these receptors is the strong concen

51 es the drugs from the diversity set, and the selective drugs from non-selective drugs.

52 ndings support that NSAIDs and the new Cox-2-selective drugs have an unsuspected target, the B cell,

53 Newer Cox-2-selective drugs have been heavily prescribed to quench i

54 Behavioural investigations using selective drugs have demonstrated that memory formation,

55 effector activity within a group of receptor-selective drugs holds the promise of increased selectivi

56 y and lower toxicity obtained with different selective drugs in respect to non-selective ones, most o

57 s avoid the TRPV1 ligand capsaicin, allowing selective, drug-inducible activation of a specific behav

58 ndescribed strategy for the design of highly selective drug inhibitors involving ligands that wrap no

59 n and stool consistency, and targeted 5-HT4R selective drug intervention has been proven beneficial i

60 immunity, the recruitment of this pathway by selective drugs is expected to attenuate the autoimmune

61 IIalpha, the primary target of many leukemia selective drugs, is low.

62 ctures of human Sirt2 in complex with highly selective drug-like inhibitors that show a unique inhibi

63 d discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavanserin, which targ

64 Therapeutically, selective drugs may improve the safety profile of benzod

65 together with the development of new subtype-selective drugs, may provide more specific and effective

66 and indicate that the development of circuit-selective drugs might alleviate sleep disorders with few

67 Previous work suggested that subtype-selective drugs might allow separating desired antihyper

68 Selective drug modulation of either TRPV1 activity or it

69 lly, due to the lack of sufficiently subtype-selective drugs or high avidity antibodies, the contribu

70 us anatomic spaces that together promote CNS selective drug partition.

71 populations of cancer cells can evade strong selective drug pressure by entering a 'persister' state

72 or selection of these silent mutations under selective drug pressure is unknown.

73 ainst influenza A (H1N1) viruses by applying selective drug pressure over multiple sequential passage

74 Under selective drug pressure, I50V/L substitutions emerge in

75 e-half of HIV-1 protease positions are under selective drug pressure, including many residues not pre

76 iated amino acid substitutions are caused by selective drug pressure, including substitutions not pre

77 The sequences of these genes, unaffected by selective drug pressure, were monophyletic.

78 nt of HIV-1 proteinase that has arisen under selective drug pressure.

79 iting, and identify mutations resulting from selective drug pressure.

80 resistance (TDR) mutations in the absence of selective drug pressure.

81 ery low detection threshold until exposed to selective drug pressure.

82 thus cannot emerge rapidly in the absence of selective drug pressure.

83 s, but that the NSAID indomethacin and Cox-2-selective drugs profoundly inhibit the ability of human

84 t chemoattraction were inhibited by the mTOR-selective drug rapamycin.

85 obalt-chaperone moiety, we have demonstrated selective drug release in the acidic and hypoxic tumor m

86 odal therapies of cancer by promoting tumour-selective drug release.

87 le Cdc25C and PP2Acalpha phosphatases in the selective drug sensitivity of del(5q) MDS.

88 s received microinfusions of the DA receptor-selective drugs SKF 81297 (0.1 or 0.4microg), SCH 23390

89 and TMS10 mutations can also induce total or selective drug susceptibility.

90 suggests that dUTPases may also represent a selective drug target in mycobacteria because of the cru

91 highlights the MEP pathway's potential as a selective drug target, which is absent in humans but ess

92 1-AR interaction offers a functionally tumor-selective drug target.

93 y demonstrates a proof of concept for tissue-selective drug targeting based on G protein-coupled rece

94 tility of a purely chemical means to achieve selective drug targeting in vivo.

95 This study provides proof of concept for selective drug targeting of proximal tubular cells on th

96 Selective drug targeting of this osteoblast signaling pa

97 P/ATP carriers, suggesting opportunities for selective drug targeting.

98 by paving the way for the development of new selective drugs targeting the amyloidogenic proteins imp

99 s more readily inhibited by NSAIDs and COX-2-selective drugs than COX-1 in platelets (e.g., log IC50+

100 d qualitatively different than those of less selective drugs that act at D2-like or serotonin (5-HT)1

101 Other, allegedly more selective drugs that affect leukocyte recruitment in the

102 The discovery of functionally selective drugs that are therapeutically effective witho

103 of many serotonin receptor subtypes enables selective drugs to be designed to therapeutically modula

104 ls were superfused with a variety of GABA(A)-selective drugs to determine their effects on [Ca(2+)](i

105 for directed design of new, more potent and selective drugs to develop an efficient treatment for Ch

106 ligands may lead to the development of more selective drugs to treat obesity or addiction with minim

107 enotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to

108 nanoarchitectural alterations, we performed selective drug treatment on the specific cytoskeletal co

109 ain benzoyl group is not essential for tumor-selective drug uptake by FRalpha.

110 s been a long standing goal in the design of selective drugs useful in implicated diseases for this p

111 Using recently developed selective drugs, we show that ATR inhibition has a signi

112 The most AF-selective drugs were associated with minimal ventricular

113 akes it difficult to predict whether subtype-selective drugs will have an improved efficacy and side-

114 This work supports the hypothesis that M4-selective drugs will prove useful to control the functio

115 ctedly and in contrast to all previous mGlu7-selective drugs, XAP044 does not act via the seven-trans

116 38,417 was effective, but the alpha1-subunit-selective drug zolpidem exacerbated social deficits.